title: The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment.
abstract: Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.
authors.affiliation: Biomedical Center, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic.
authors.forename: Lubos
authors.initials: L
authors.lastname: Holubec
authors.affiliation: Biomedical Center, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic Department of Histology and Embryology, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic polivkajiri@gmail.com.
authors.forename: Jiri
authors.initials: J
authors.lastname: Polivka
authors.affiliation: Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic.
authors.forename: Martin
authors.initials: M
authors.lastname: Safanda
authors.affiliation: Department of Haematology and Oncology, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Michal
authors.initials: M
authors.lastname: Karas
authors.affiliation: Biomedical Center, Faculty of Medicine Plzen, Charles University in Prague, Pilsen, Czech Republic.
authors.forename: Vaclav
authors.initials: V
authors.lastname: Liska
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology*; D000068818:Cetuximab / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D007107:Immune System; D007167:Immunotherapy / Q000379:methods; D000077544:Panitumumab
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab
keywords: Colorectal cancer; cetuximab; immune response; immunomodulation; review; targeted therapy